Quadrant Capital Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Quadrant Capital Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,000	Closed	-$536K	–	2782
2023 Q4	$536K	Buy	+6,000	New	+$446K	0.05%	287
2023 Q2	–	Sell	-261	Closed	-$19.9K	–	2780
2023 Q1	$19.9K	Sell	261 -825	-76%	-$68.5K	﹤0.01%	1704
2022 Q4	$90.1K	Buy	1,086 +760	+233%	+$61.5K	0.01%	841
2022 Q3	$26K	Hold	326	–	–	﹤0.01%	1418
2022 Q2	$24K	Buy	326 +152	+87%	+$11.4K	﹤0.01%	1221
2022 Q1	$16K	Buy	+174	New	+$16.1K	﹤0.01%	1451

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrant Capital Group's XBI Position: Q1 2024 in Review

Quadrant Capital Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 6,000 shares — an estimated $536K sold.

Quadrant Capital Group first reported a position in XBI in Q1 2022 and held it in 6 quarters. The position peaked at $536K in Q4 2023. 782 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

Quadrant Capital Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
Quadrant Capital Group sold 6,000 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $536K.
Quadrant Capital Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 6 quarters.
Quadrant Capital Group's State Street SPDR S&P Biotech ETF position peaked at $536K in Q4 2023.
782 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Quadrant Capital Group's 13F filing for Q1 2024, filed 15 May 2024.